Name: Fmoc-VC-PAB-MMAE
Brand: BOC Sciences
Rating: 5 (1 reviews)

Size

Price

Stock

Quantity

$--

In stock

Synonyms

Fmoc-Val-Cit-PAB-MMAE; CS-5428; CS 5428; CS5428

IUPAC Name

[4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate

Canonical SMILES

CCC(C)C(C(CC(=O)N1CCCC1C(C(C)C(=O)NC(C)C(C2=CC=CC=C2)O)OC)OC)N(C)C(=O)C(C(C)C)NC(=O)C(C(C)C)N(C)C(=O)OCC3=CC=C(C=C3)NC(=O)C(CCCNC(=O)N)NC(=O)C(C(C)C)NC(=O)OCC4C5=CC=CC=C5C6=CC=CC=C46

InChI

InChI=1S/C73H104N10O14/c1-15-45(8)63(58(94-13)39-59(84)83-38-24-32-57(83)65(95-14)46(9)66(86)76-47(10)64(85)49-25-17-16-18-26-49)81(11)70(90)61(43(4)5)79-69(89)62(44(6)7)82(12)73(93)97-40-48-33-35-50(36-34-48)77-67(87)56(31-23-37-75-71(74)91)78-68(88)60(4

InChIKey

RHQGFVOXIOMBMC-UUMMFNFXSA-N

Solubility

10 mm in DMSO

Appearance

Soild powder

Quantity

Milligrams-Grams

Shelf Life

As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly

Shipping

Room temperature

Storage

-20°C Freeze

Fmoc-VC-PAB-MMAE is a conjugate used in targeted cancer therapy, particularly in the development of antibody-drug conjugates (ADCs). Here are some key applications of Fmoc-VC-PAB-MMAE:

Targeted Drug Delivery: Fmoc-VC-PAB-MMAE is utilized to create antibody-drug conjugates (ADCs) that deliver cytotoxic drugs selectively to cancer cells. By attaching this conjugate to a monoclonal antibody, the drug can be directed to tumor cells expressing specific antigens. This targeted approach minimizes damage to healthy tissues and enhances the therapeutic index of the drug.

Cancer Treatment: This conjugate has shown promising results in cancer therapy by being an effective payload in ADCs for killing cancer cells. It combines targeted delivery with the potent cytotoxic effect of MMAE, improving the efficacy of cancer treatment. Clinical trials have demonstrated its potential in treating various types of cancers, including lymphoma and breast cancer.

Research and Development: Fmoc-VC-PAB-MMAE is valuable in the preclinical development of new therapeutic agents. Researchers use this conjugate to explore different linker and payload combinations for ADCs. This enables the optimization of ADC stability, efficacy, and safety profiles before advancing to clinical studies.

Pharmacokinetics and Biodistribution Studies: The conjugate is utilized in pharmacokinetic and biodistribution studies to understand how the drug is distributed, metabolized, and eliminated in the body. By studying its behavior in vivo, researchers can optimize the dosing regimens and reduce potential toxicity. This information is crucial for the successful clinical translation of new ADC therapies.

Catalog	Product Name	CAS
BADC-00849	Acetylene-linker-Val-Cit-PABC-MMAE	1411977-95-1
BADC-01448	mDPR-Val-Cit-PAB-MMAE	1491152-26-1
BADC-00958	Amino-PEG4-Val-Cit-PAB-MMAE	1492056-71-9
BADC-01348	Val-Cit-PAB-MMAE TFA salt	1608127-32-7
BADC-01435	N-Ac-Cys-MC-VC-PAB-MMAE	1628933-80-1
BADC-01408	DBM(C6)-VC-PAB-MMAE	1644228-55-6
BADC-01459	MC-betaglucuronide-MMAE-1	1703778-92-0
BADC-01638	OH-Glu-Val-Cit-PAB-MMAE	1895916-23-0
BADC-00855	SuO-Glu-Val-Cit-PAB-MMAE	1895916-24-1
BADC-01413	DBM-MMAE	1912408-87-7